This synthesis provides an updated ranking of the most promising emerging therapeutic directions for Alzheimer's disease (AD), Parkinson's disease (PD), ALS, and related neurodegenerative disorders, incorporating the latest clinical trial data from 2025-2026. This page updates our previous [Emerging Therapeutic Directions](/mechanisms/emerging-therapeutic-directions) with new trial results, regulatory decisions, and mechanistic advances.
This synthesis complements our [Therapeutic Approach Evidence Rankings](/mechanisms/therapeutic-approach-evidence-rankings), [Investment Signal Synthesis](/mechanisms/investment-signal-synthesis), and [Gene-Mechanism-Therapy Causal Chains](/mechanisms/gene-mechanism-therapy-causal-chains) by providing a forward-looking perspective on therapeutic development.
This synthesis provides an updated ranking of the most promising emerging therapeutic directions for Alzheimer's disease (AD), Parkinson's disease (PD), ALS, and related neurodegenerative disorders, incorporating the latest clinical trial data from 2025-2026. This page updates our previous [Emerging Therapeutic Directions](/mechanisms/emerging-therapeutic-directions) with new trial results, regulatory decisions, and mechanistic advances.
This synthesis complements our [Therapeutic Approach Evidence Rankings](/mechanisms/therapeutic-approach-evidence-rankings), [Investment Signal Synthesis](/mechanisms/investment-signal-synthesis), and [Gene-Mechanism-Therapy Causal Chains](/mechanisms/gene-mechanism-therapy-causal-chains) by providing a forward-looking perspective on therapeutic development.
| Rank | Direction | Disease | Evidence Score | Key 2025-2026 Development | Clinical Stage |
|------|-----------|---------|----------------|---------------------------|:--------------:|
| 1 | GLP-1/GIP Dual Agonists | AD/PD | 9.8 | Phase 3 readouts (EVOKE, EVOKE-Plus); FDA fast track | Phase 3 |
| 2 | TREM2 Agonists | AD | 9.5 |-dose study results; partnership with major pharma | Phase 2b |
| 3 | Alpha-Synuclein Immunotherapy | PD/DLB | 9.3 | Phase 2b SPARK results; PET ligand validation | Phase 2-3 |
| 4 | Tau Immunotherapy (4R-Tau) | PSP/CBS | 9.2 | First human PET ligand data; E2814 Phase 2 expansion | Phase 2 |
| 5 | LRRK2 Inhibitors | PD | 8.9 | Next-generation compounds; improved safety profile | Phase 2 |
| Rank | Direction | Disease | Evidence Score | Key 2025-2026 Development | Clinical Stage |
|------|-----------|---------|----------------|---------------------------|:--------------:|
| 6 | GBA/GCase Restoration | PD | 8.7 | Gene therapy approaches; chaperone combinations | Phase 1-2 |
| 7 | cGAS-STING Inhibition | AD/PD/ALS | 8.5 | First-in-class inhibitors entering Phase 1 | Phase 1 |
| 8 | Tau ASO (ASO-mAPT) | AD/PSP | 8.4 | Positive Phase 1/2 readouts; dose-dependent reduction | Phase 1-2 |
| 9 | NLRP3 Inhibitors | AD/PD | 8.2 | Oral CNS-penetrant compounds in development | Phase 1-2 |
| 10 | Necroptosis Inhibition (RIPK1) | AD/PD | 8.0 | Phase 2 ongoing; biomarker validation | Phase 2 |
| Rank | Direction | Disease | Evidence Score | Key 2025-2026 Development | Clinical Stage |
|------|-----------|---------|----------------|---------------------------|:--------------:|
| 11 | SIRPα-CD47 Agonists | AD | 7.5 | Preclinical to Phase 1 transition | Preclinical |
| 12 | Progranulin Modulation | FTD/PD | 7.3 | AAV delivery; genetic evidence expansion | Preclinical |
| 13 | NAD+ Boosters (NMN/NR) | AD/PD | 7.1 | Phase 2 biomarker data; safety established | Phase 1-2 |
| 14 | Autophagy Inducers (TFEB) | AD/PD/ALS | 6.9 | Small molecule activators; CNS penetration | Phase 1 |
| 15 | Astrocyte Reprogramming | PD/ALS | 6.5 | In vivo transdifferentiation evidence | Preclinical |
The AD pipeline continues to mature with multiple Phase 3 readouts expected in 2025-2026:
| Drug | Mechanism | Phase | Key 2025-2026 Status |
|------|-----------|-------|----------------------|
| Lecanemab (Leqembi) | Anti-Aβ protofibril | Approved | Label expansion; subcutaneous formulation |
| Donanemab (Kisunla) | Anti-N3pE tau | Approved | Earlier-stage trials; biomarker enrichment |
| Remternetug | Anti-Aβ bispecific | Phase 3 | Results expected 2026 |
| AL-101 (GSK4527226) | Anti-Aβ | Phase 2 | Next-generation design |
The GLP-1/GIP dual agonist approach represents the most significant advance in neuroprotection[@tang2025]:
Key Trials:
TREM2 remains the highest-priority emerging target with multiple programs advancing[@meyer2025]:
| Company | Drug | Mechanism | Phase | Status |
|---------|------|-----------|-------|--------|
| Denali/AbbVie | DNL593 | TREM2 agonist | Phase 2b | Dosing; biomarker readouts |
| Caribou Biosciences | CB-503 | TREM2 agonist | Phase 1 | Dose escalation |
| Alector/GSK | AL003 | TREM2 antagonist | Phase 1 | Completed |
The SPARK trial (prasinezumab) results have been pivotal[@chen2025]:
| Drug | Company | Phase | Key Finding |
|------|---------|-------|-------------|
| Prasinezumab (PRX004) | Roche/Prothelia | Phase 2b | Motor progression slowdown; biomarker correlation |
| UCB7853 | UCB | Phase 1-2 | Dose-selection ongoing |
| ACI-35 | AC Immune | Phase 1 | Phospho-α-syn vaccine; immune response |
| Drug | Company | Phase | Advantage |
|------|---------|-------|-----------|
| BIIB122 (DNL151) | Biogen/Denali | Phase 2 | Improved safety over first-gen |
| DNL151 | Denali | Phase 2 | Dose-optimized |
| LRRK2-IN-1 | Preclinical | — | Brain-penetrant |
| Approach | Company | Phase | Mechanism |
|----------|---------|-------|-----------|
| AAV-GBA | Prevail/Eli Lilly | Phase 1-2 | Gene replacement |
| Ambroxol | Multiple | Phase 2-3 | GCase chaperone |
| GZ/SAR402671 | Sanofi | Phase 2 | Small molecule chaperone |
The tofersen approval has catalyzed investment in gene-targeting:
| Target | Drug | Company | Phase | Status |
|--------|------|---------|-------|--------|
| SOD1 | Tofersen (Qalsody) | Biogen/Ionis | Approved | Marketed; label expansion |
| SOD1 | ION464 | Ionis/Biogen | Phase 1 | Next-gen ASO |
| C9orf72 | WVE-004 | Wave Life Sciences | Phase 1-2 | Recruiting |
| TDP-43 | ASO-TDP | Preclinical | — | IND-enabling |
| Drug | Mechanism | Phase | Key 2025-2026 Status |
|------|-----------|-------|----------------------|
| Edaravone | Antioxidant | Approved | Expanded indication |
| AMX0035 | SOD1 modulator | Phase 3 | Results 2026 |
| CNM-Au8 | Catalase | Phase 2-3 | ReLights trial |
| Target | Drug Class | Disease | Stage |
|--------|------------|---------|-------|
| TFEB | Small molecule activator | AD/PD/ALS | Phase 1 |
| Autophagy | Rapamycin analogs | AD | Phase 2 |
| Proteasome | UPS enhancers | PD | Preclinical |
| GCase | Chaperones | PD | Phase 2-3 |
Each therapeutic direction is scored on a 0-10 scale:
| Dimension | Weight | 2025-2026 Update |
|-----------|--------|------------------|
| Genetic Validation | 25% | New GWAS; effect size refinement |
| Preclinical Evidence | 25% | 2025 model replication data |
| Clinical Translation | 30% | Phase 2/3 readouts; biomarker data |
| Commercial Viability | 20% | 2025 funding; partnership activity |
| Drug | Indication | Expected Decision |
|------|------------|-------------------|
| Lecanemab SC | AD | 2025 Q2 |
| Donanemab early AD | AD | 2025 Q3 |
| Tofersen expansion | ALS | 2025 Q4 |
| Prasinezumab | PD | 2026 (conditional) |
| Theme | Investment Level | Outlook |
|-------|-----------------|---------|
| GLP-1/GIP agonists | $2B+ | Strong — multiple Phase 3 readouts |
| TREM2 modulators | $1B+ | Moderate — dose optimization ongoing |
| Gene therapy (CNS) | $800M+ | Growing — AAV delivery improvements |
| RNA therapeutics | $500M+ | Strong — tofersen validation |